Microart Inc. (MCRT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMicroart Inc. (MCRT) trades at $0.0002. Microart Inc. focuses on researching and developing stem cell solutions and therapeutic applications. The company also commercializes cell-based anti-aging research and cosmetic products, and develops proprietary technology for diabetes treatment. Sector: Technology.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for MCRT: MCRT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Microart Inc. (MCRT) Technology Profile & Competitive Position
Microart Inc., founded in 1980 and based in Hong Kong, operates in the biotechnology sector, focusing on stem cell research and therapeutic applications. The company develops and commercializes cell-based anti-aging products and is also developing technology for diabetes treatment, positioning itself within the competitive healthcare landscape.
What Is the Investment Thesis for MCRT?
Microart Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its focus on stem cell research and therapeutic applications. The company's development of cell-based anti-aging products and diabetes treatment technologies could drive future revenue growth. However, the company's OTC listing and lack of financial data necessitate caution. Key catalysts include potential breakthroughs in its diabetes treatment technology and successful commercialization of its anti-aging products. Risks include the inherent uncertainty of biotechnology research, the competitive landscape, and the challenges associated with operating as an OTC-listed company with limited financial transparency. Investors should conduct thorough due diligence and assess their risk tolerance before considering an investment in Microart Inc.
Based on FMP financials and quantitative analysis
MCRT Key Highlights
Microart Inc. was founded in 1980, indicating a long-standing presence in the biotechnology industry.
- The company focuses on stem cell research and therapeutic applications, a high-growth area within healthcare.
- Microart Inc. develops and commercializes cell-based anti-aging research and cosmetic products, providing a diversified revenue stream.
- The company is developing proprietary technology for the treatment of diabetes, addressing a significant global health challenge.
- Microart Inc. is based in Kowloon City, Hong Kong, positioning it within the Asian healthcare market.
Who Are MCRT's Competitors?
MCRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NEON Neonode Inc. | $0.92 | +2.19% | $15.5M | — |
| HOLO MicroCloud Hologram Inc. | $1.56 | -1.89% | $20.6M | 36 5-pillar |
| DAIO Data I/O Corporation | $2.98 | +1.36% | $30.6M | — |
| NSYS Nortech Systems Incorporated | $11.58 | +5.66% | $32.4M | 71 5-pillar |
| LGL The LGL Group, Inc. | $7.23 | +2.70% | $41.0M | 39 5-pillar |
| MIND MIND Technology, Inc. | $4.51 | -1.74% | $41.0M | 37 5-pillar |
| ACFN Acorn Energy, Inc. | $19.02 | -1.71% | $47.7M | 37 5-pillar |
| CPSH CPS Technologies Corporation | $3.84 | +1.32% | $62.0M | 39 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCRT's Key Strengths?
Proprietary stem cell technologies.
- Focus on both therapeutic and cosmetic applications.
- Long-standing presence in the biotechnology industry (founded in 1980).
- Development of technology for diabetes treatment.
What Are MCRT's Weaknesses?
OTC listing, indicating higher risk and lower liquidity.
- Limited financial information available.
- Small market capitalization ($0.00B).
- Dependence on research and development success.
What Are the Key Risks for MCRT?
Failure to obtain regulatory approvals for new products.
- Intense competition in the biotechnology industry.
- Economic downturns affecting consumer spending on cosmetic products.
- Limited financial disclosure and transparency due to OTC listing.
- Risk of research and development failures.
What Are MCRT's Competitive Advantages?
- Proprietary stem cell technologies.
- Established presence in the Hong Kong market.
- Focus on both therapeutic and cosmetic applications.
- Expertise in adult stem cell research.
What Does MCRT Do?
Microart Inc., established in 1980 and headquartered in Kowloon City, Hong Kong, is a biotechnology company focused on the research, development, and commercialization of stem cell solutions. The company's core business revolves around leveraging adult stem cells for therapeutic applications and developing innovative products in the anti-aging and cosmetic sectors. Microart Inc. is also actively involved in developing proprietary technologies aimed at treating diabetes, showcasing its commitment to addressing significant healthcare challenges. Microart Inc.'s product portfolio includes cell-based anti-aging research and cosmetic products, which are marketed to consumers seeking advanced skincare solutions. The company's research efforts are directed towards harnessing the regenerative potential of stem cells to develop effective therapies for various conditions. The company operates primarily in Hong Kong, with potential for expansion into other markets as its research and development efforts progress. Microart Inc. competes with other biotechnology companies in the stem cell research and therapeutic development space. Its focus on adult stem cells and its diversified product portfolio, spanning both therapeutic and cosmetic applications, differentiates it from some of its competitors. The company's long-standing presence in the industry, since 1980, provides it with valuable experience and insights into the evolving healthcare landscape.
What Products and Services Does MCRT Offer?
- Researches and develops stem cell solutions.
- Develops therapeutic applications of adult stem cells.
- Commercializes cell-based anti-aging research products.
- Commercializes cell-based cosmetic products.
- Develops proprietary technology for diabetes treatment.
- Focuses on leveraging adult stem cells for regenerative medicine.
How Does MCRT Make Money?
- Develops and patents stem cell technologies.
- Commercializes anti-aging and cosmetic products directly to consumers.
- Seeks partnerships for therapeutic applications of stem cells.
- Generates revenue through product sales and potential licensing agreements.
What Industry Does MCRT Operate In?
Microart Inc. operates in the biotechnology industry, a sector characterized by rapid innovation, high research and development costs, and significant regulatory oversight. The global biotechnology market is projected to reach $3.44 trillion by 2030, driven by advancements in genomics, proteomics, and stem cell research. Microart Inc.'s focus on stem cell solutions and therapeutic applications aligns with these trends. The company competes with other biotechnology firms, including CBDX, CLABF, ENDV, GMVDF, and HAVLF, that are also developing innovative therapies and products.
Who Are MCRT's Key Customers?
- Consumers seeking anti-aging and cosmetic products.
- Patients with diabetes (potential future market).
- Research institutions and pharmaceutical companies (potential partners).
- Healthcare providers (potential future market).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Microart Inc. operates in the Technology sector. It is headquartered in Hong Kong, HK. MCRT has traded publicly since 2010.
MCRT Latest News
No recent news available for MCRT.
MCRT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MCRT.
Price Targets
Wall Street price target analysis for MCRT.
MCRT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MCRT; grades run from A+ (80-100) to F (below 30).
Leadership: Tsap Wai Ping
CEO
Information on Tsap Wai Ping's background is limited. As the CEO of Microart Inc., Tsap Wai Ping is responsible for leading the company's strategic direction, overseeing its research and development efforts, and managing its overall operations.
Track Record: Due to limited information, it is not possible to assess Tsap Wai Ping's track record at Microart Inc. Key achievements, strategic decisions, and company milestones under their leadership are currently unknown. Further information is needed to evaluate their performance and contributions to the company's success.
MCRT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Microart Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Lack of regulatory oversight and investor protection.
- Going Concern Risk: The company's ability to continue as a going concern may be uncertain.
- Verify the company's legal status and registration.
- Assess the company's management team and their experience.
- Attempt to obtain and review any available financial statements.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Long-standing presence in the biotechnology industry (founded in 1980).
- Focus on stem cell research and therapeutic applications.
- Development of proprietary technology for diabetes treatment.
- Commercialization of cell-based anti-aging products.
MCRT Technology Stock FAQ
What do analysts say about MCRT stock?
There is currently no available analyst coverage or consensus on Microart Inc. (MCRT) due to its OTC listing and limited financial disclosure.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Microart Inc. due to its OTC listing and lack of financial disclosure.